Effects of aspirin on markers of inflammation and coagulation in subclinical atherosclerosis in type 2 diabetic subjects.
Completed
- Conditions
- Diabetes Mellitus type 2, no cardiovascular disease.
- Registration Number
- NL-OMON23321
- Lead Sponsor
- eiden University Medical Center (LUMC), department of General Internal Medicine
- Brief Summary
1. J Thromb Haemost. 2007 Jul;5(7):1562-4. Epub 2007 Apr 19. <br> 2. Diabetes Obes Metab. 2008 Aug;10(8):668-74. Epub 2007 Nov 22.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Diabetes mellitus type 2;
2. Age >18 year;
Exclusion Criteria
1. History of myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, proven manifest coronary artery disease, angina pectoris, heart failure or severe cardiac arrhythmia;
2. History of cerebrovascular accident, transient ischemic attack;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Markers of vascular wall inflammation, represented by hsCRP and Il-6.
- Secondary Outcome Measures
Name Time Method 1. Prostaglandin production, represented by 11-dehydro-thromboxaneB2, 8-isoprostaglandineF2á and 2,3-dinor-6-keto-prostaglandineF1á measured in morning-urine samples;<br /><br>2. Vascular wall adhesion molecules, represented by sICAM-1, p-selectin, MCSF, CD40L;<br /><br>3. Coagulation markers, represented by fibrinogen, vWillebrand Factor and PAI-1 activity.